Revance Therapeutics Inc (FRA:RTI)
€ 3.5 -0.08 (-2.23%) Market Cap: 358.58 Mil Enterprise Value: 642.04 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 68/100

Revance Therapeutics Inc at Barclays Global Healthcare Conference Transcript

Mar 13, 2019 / 07:50PM GMT
Release Date Price: €14.11 (-1.95%)
Tobin C. Schilke
Revance Therapeutics, Inc. - CFO

Thank you very much and good afternoon. I'm Toby Schilke, CFO of Revance. And I'm pleased to share our story of sort of where we've gotten to with Revance and the exciting potential future that we have in the next coming years. This presentation contains forward-looking statements, I encourage you to read them in detail on our website.

As you're well aware, Revance is on the cusp of entering the neuromodulator marketplace. And before I talk about our specific offering and our differentiated premium offering to that marketplace, I'd like to take a step back and give you some thoughts on the overall neuromodulator marketplace.

First of all, it's a large and growing area and we'll talk on the sales potential of that. There are 100 of potential indications possible. In the U.S. there are 4 currently approved products, none of them have a wide amount of clinical differentiation from their labels. They provide release not only from aesthetics conditions like crow's feet, lateral canthal lines or glabellar lines, but also those suffering

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot